Dermapharm Holding SE
DMPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $346,050 | $272,146 | $302,396 | $290,670 |
| % Growth | 27.2% | -10% | 4% | – |
| Cost of Goods Sold | $219,933 | $88,015 | $103,211 | $97,491 |
| Gross Profit | $126,117 | $184,131 | $199,185 | $193,179 |
| % Margin | 36.4% | 67.7% | 65.9% | 66.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $55,000 | $0 | $75,382 | $79,016 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$4,982 | $139,645 | $64,015 | $66,307 |
| Operating Expenses | $50,018 | $139,645 | $139,397 | $145,323 |
| Operating Income | $76,099 | $44,486 | $59,788 | $47,856 |
| % Margin | 22% | 16.3% | 19.8% | 16.5% |
| Other Income/Exp. Net | -$11,374 | -$11,960 | -$10,121 | -$13,303 |
| Pre-Tax Income | $64,725 | $32,526 | $49,667 | $34,553 |
| Tax Expense | $16,487 | $11,633 | $16,470 | $15,503 |
| Net Income | $48,375 | $20,894 | $33,405 | $20,508 |
| % Margin | 14% | 7.7% | 11% | 7.1% |
| EPS | 0.9 | 0.39 | 0.62 | 0.38 |
| % Growth | 130.8% | -37.1% | 63.2% | – |
| EPS Diluted | 0.9 | 0.39 | 0.62 | 0.38 |
| Weighted Avg Shares Out | 53,840 | 53,574 | 53,879 | 53,963 |
| Weighted Avg Shares Out Dil | 53,840 | 53,574 | 53,879 | 53,963 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,840 | $1,328 | $2,390 | -$2,636 |
| Interest Expense | $17,230 | $13,177 | $12,877 | $11,530 |
| Depreciation & Amortization | $24,699 | $20,356 | $19,986 | $26,161 |
| EBITDA | $106,638 | $66,059 | $82,530 | $72,244 |
| % Margin | 30.8% | 24.3% | 27.3% | 24.9% |